acapatamab

DRUG2 trials

Sponsors

Amgen

Conditions

Metastatic Castration-resistant Prostate CancerProstate Cancer

Phase 1

Safety, Tolerability, Pharmacokinetics, and Efficacy of Acapatamab in Subjects With mCRPC

TerminatedNCT03792841

AmgenMetastatic Castration-resistant Prostate Cancer, Prostate Cancer

Start: 2019-02-05End: 2023-06-29Updated: 2025-10-16

Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC)

TerminatedNCT04631601

AmgenMetastatic Castration-resistant Prostate Cancer

Start: 2021-01-15End: 2023-10-23Updated: 2025-10-07

Related Papers

Characterization and root cause analysis of immunogenicity to pasotuxizumab (AMG 212), a prostate-specific membrane antigen-targeting bispecific T-cell engager therapy

Frontiers in Immunology2023-10-2320 citations

Safety and efficacy of AMG 160, a half-life extended BiTE immune therapy targeting prostate-specific membrane antigen (PSMA), and other therapies for metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology2021-05-2013 citations

340 Phase 1 study of AMG 160, a half-life extended BiTE® (bispecific T-cell engager) therapy targeting prostate-specific membrane antigen, in patients with metastatic castration-resistant prostate cancer

Regular and Young Investigator Award Abstracts2020-11-012 citations

717 AMG 160, a prostate-specific membrane antigen (PSMA)-targeted BiTE<sup>®</sup> immuno-oncology therapy, is active in models of advanced prostate cancer that are resistant to radioligand therapy

Regular and Young Investigator Award Abstracts2020-11-011 citations

Phase I study of AMG 160, a half-life extended bispecific T-cell engager (HLE BiTE immune therapy) targeting prostate-specific membrane antigen, in patients with metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology2020-05-206 citations

Phase I study of AMG 160, a half-life extended bispecific T-cell engager (HLE BiTE) immune therapy targeting prostate-specific membrane antigen (PSMA), in patients with metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology2020-02-1924 citations

Combination of AMG 160, a PSMA x CD3 half-life extended bispecific T-cell engager (HLE BiTE) immune therapy, with an anti-PD-1 antibody in prostate cancer (PCa).

Journal of Clinical Oncology2020-02-197 citations